• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

植物雌激素用于治疗更年期血管舒缩症状。

Phytoestrogens for vasomotor menopausal symptoms.

作者信息

Lethaby A E, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J

机构信息

University of Auckland, O&G FMHS, Grafton Rd, Private Bag 92019, Auckland, New Zealand, 1142.

出版信息

Cochrane Database Syst Rev. 2007 Oct 17(4):CD001395. doi: 10.1002/14651858.CD001395.pub3.

DOI:10.1002/14651858.CD001395.pub3
PMID:17943751
Abstract

BACKGROUND

Vasomotor symptoms, such as hot flushes and night sweats, are very common during the menopausal transition. Hormone replacement therapy has traditionally been used as a very effective treatment but concerns over increased risks of some chronic diseases have markedly increased the interest of women in alternatives. Some of the most popular of these are treatments based on foods or supplements enriched with phytoestrogens, plant-derived chemicals that have oestrogenic action.

OBJECTIVES

To assess the efficacy, safety and acceptability of foods and supplements based on high levels of phytoestrogens for reducing hot flushes and night sweats in postmenopausal women.

SEARCH STRATEGY

Searches were undertaken of the following electronic databases: the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of randomised trials, Cochrane Register of Controlled Trials (CENTRAL) (March 2007), MEDLINE (1966 to March 2007), EMBASE (1980 to March 2007), AMED (1985 to March 2007), PsycINFO (1986 to March 2007) and CINAHL (1982 to March 2007). Attempts were made to access grey literature by letters to pharmaceutical companies and searches of ongoing trial registers. Reference lists of included trials were also searched.

SELECTION CRITERIA

Studies were included if they were randomised, had peri- or postmenopausal participants with vasomotor symptoms, a duration of at least 12 weeks and where the intervention was a food or supplement with high levels of phytoestrogens (and not combined with other herbal treatments). Trials of women who had breast cancer or a history of breast cancer were excluded.

DATA COLLECTION AND ANALYSIS

Selection of trials, data extraction and quality assessment were undertaken by at least two authors. Most of the trials were too dissimilar to combine in meta-analysis and their results are provided in table format. Studies were grouped into broad categories: dietary soy, soy extracts, red clover extracts and other types of phytoestrogen. Five trials used Promensil, a red clover extract; these trials were combined in a meta-analysis and summary effect measures were calculated.

MAIN RESULTS

Thirty trials comparing phytoestrogens with control met the inclusion criteria. Very few trials had data suitable for combining in meta-analysis. Of the five trials with data suitable for pooling that assessed daily frequency of hot flushes, there was no significant difference overall in the frequency of hot flushes between Promensil (a red clover extract) and placebo (WMD=-0.6, 95% CI -1.8 to 0.6). There was no evidence of a difference in percentage reduction in hot flushes in two trials between Promensil and placebo (WMD=20.2, 95% CI -12.1 to 52.4). Individual results from the remaining trials were compared. Some of the trials found that phytoestrogen treatments alleviated the frequency and severity of hot flushes and night sweats when compared to placebo but many of the trials were of low quality and were underpowered. There was a strong placebo effect in most trials with a reduction in frequency ranging from 1% to 59% with placebo. There was no indication that the discrepant results were due to the amount of isoflavone in the active treatment arm, the severity of vasomotor symptoms or trial quality factors. There was also no evidence that the treatments caused oestrogenic stimulation of the endometrium (an adverse effect) when used for up to two years.

AUTHORS' CONCLUSIONS: There is no evidence of effectiveness in the alleviation of menopausal symptoms with the use of phytoestrogen treatments.

摘要

背景

血管舒缩症状,如潮热和盗汗,在绝经过渡期间非常常见。传统上,激素替代疗法一直被用作一种非常有效的治疗方法,但对某些慢性病风险增加的担忧显著提高了女性对替代疗法的兴趣。其中一些最受欢迎的替代疗法是基于富含植物雌激素的食物或补充剂的治疗方法,植物雌激素是具有雌激素作用的植物衍生化学物质。

目的

评估基于高含量植物雌激素的食物和补充剂在减轻绝经后女性潮热和盗汗方面的疗效、安全性和可接受性。

检索策略

对以下电子数据库进行了检索:Cochrane月经失调与生育力低下小组随机试验专门注册库、Cochrane对照试验注册库(CENTRAL)(2007年3月)、医学索引数据库(MEDLINE,1966年至2007年3月)、荷兰医学文摘数据库(EMBASE,1980年至2007年3月)、联合和补充医学数据库(AMED,1985年至2007年3月)、心理学文摘数据库(PsycINFO,1986年至2007年3月)和护理学与健康领域数据库(CINAHL,1982年至2007年3月)。通过写信给制药公司以及检索正在进行的试验注册库来获取灰色文献。还检索了纳入试验的参考文献列表。

选择标准

纳入的研究需为随机对照试验,参与者为有血管舒缩症状的围绝经期或绝经后女性,干预持续时间至少12周,且干预措施为高含量植物雌激素的食物或补充剂(不与其他草药治疗联合使用)。排除患有乳腺癌或有乳腺癌病史的女性的试验。

数据收集与分析

至少两名作者进行试验选择、数据提取和质量评估。大多数试验差异太大,无法进行荟萃分析,其结果以表格形式呈现。研究分为几大类:膳食大豆、大豆提取物、红三叶草提取物和其他类型的植物雌激素。五项试验使用了红三叶草提取物Promensil;这些试验进行了荟萃分析并计算了汇总效应量。

主要结果

30项比较植物雌激素与对照的试验符合纳入标准。很少有试验有适合进行荟萃分析的数据。在五项有适合合并数据且评估潮热每日发作频率的试验中,Promensil(一种红三叶草提取物)与安慰剂相比,潮热发作频率总体上无显著差异(加权均数差=-0.6,95%置信区间-1.8至0.6)。在两项试验中,Promensil与安慰剂相比,潮热减轻百分比无差异的证据(加权均数差=20.2,95%置信区间-12.1至52.4)。对其余试验的个体结果进行了比较。一些试验发现,与安慰剂相比,植物雌激素治疗可减轻潮热和盗汗的频率及严重程度,但许多试验质量较低且效能不足。大多数试验中存在较强的安慰剂效应,安慰剂使发作频率降低1%至59%。没有迹象表明结果差异是由于活性治疗组中异黄酮的含量、血管舒缩症状的严重程度或试验质量因素所致。也没有证据表明这些治疗在使用长达两年时会引起子宫内膜的雌激素刺激(一种不良反应)。

作者结论

没有证据表明使用植物雌激素治疗能有效缓解更年期症状。

相似文献

1
Phytoestrogens for vasomotor menopausal symptoms.植物雌激素用于治疗更年期血管舒缩症状。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD001395. doi: 10.1002/14651858.CD001395.pub3.
2
Phytoestrogens for menopausal vasomotor symptoms.植物雌激素用于治疗更年期血管舒缩症状。
Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD001395. doi: 10.1002/14651858.CD001395.pub4.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
5
Herbal and dietary therapies for primary and secondary dysmenorrhoea.原发性和继发性痛经的草药及饮食疗法。
Cochrane Database Syst Rev. 2001(3):CD002124. doi: 10.1002/14651858.CD002124.
6
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.口服雌激素及雌激素/孕激素联合治疗与安慰剂治疗潮热的比较
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD002978. doi: 10.1002/14651858.CD002978.pub2.
7
Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.用于治疗月经过多的孕激素或释放孕激素的宫内节育系统。
Cochrane Database Syst Rev. 2005 Oct 19(4):CD002126. doi: 10.1002/14651858.CD002126.pub2.
8
Interventions for infantile haemangiomas of the skin.皮肤婴儿血管瘤的干预措施。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3.
9
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.
10
Treatments for seizures in catamenial (menstrual-related) epilepsy.月经性(与月经相关)癫痫发作的治疗。
Cochrane Database Syst Rev. 2021 Sep 16;9(9):CD013225. doi: 10.1002/14651858.CD013225.pub3.

引用本文的文献

1
Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review).黄酮类化合物在胃肠道癌中的治疗潜力:聚焦信号通路及改善策略(综述)
Mol Med Rep. 2025 Apr;31(4). doi: 10.3892/mmr.2025.13474. Epub 2025 Feb 28.
2
Focusing on Formononetin: Recent Perspectives for its Neuroprotective Potentials.聚焦于芒柄花黄素:其神经保护潜力的最新观点。
Front Pharmacol. 2022 May 30;13:905898. doi: 10.3389/fphar.2022.905898. eCollection 2022.
3
Postmenopausal women in gynecological care.接受妇科护理的绝经后女性。
Prz Menopauzalny. 2021 Jun;20(2):88-98. doi: 10.5114/pm.2021.107103. Epub 2021 Jun 18.
4
The Effect of YT1 (MENOLACTO) on Improving Menopausal Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.YT1(美诺拉克托)对改善更年期症状的影响:一项随机、双盲、安慰剂对照临床试验。
J Clin Med. 2020 Jul 9;9(7):2173. doi: 10.3390/jcm9072173.
5
Scientific Papers and Patents on Substances with Unproven Effects. Part 2.关于效果未经证实物质的科学论文与专利。第2部分。
Recent Pat Drug Deliv Formul. 2019;13(3):160-173. doi: 10.2174/1872211313666190819124752.
6
Isoflavones.异黄酮。
Molecules. 2019 Mar 19;24(6):1076. doi: 10.3390/molecules24061076.
7
Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.血管舒缩症状贯穿更年期过渡:女性之间的差异。
Obstet Gynecol Clin North Am. 2018 Dec;45(4):629-640. doi: 10.1016/j.ogc.2018.07.005. Epub 2018 Oct 25.
8
A Hop Extract Lifenol® Improves Postmenopausal Overweight, Osteoporosis, and Hot Flash in Ovariectomized Rats.Hop 提取物 Lifenol® 可改善去卵巢大鼠的绝经后超重、骨质疏松症和热潮红。
Evid Based Complement Alternat Med. 2018 Feb 12;2018:2929107. doi: 10.1155/2018/2929107. eCollection 2018.
9
Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.女性为何选择复方生物同源激素疗法:绝经决策定性研究的经验教训
BMC Womens Health. 2017 Oct 2;17(1):97. doi: 10.1186/s12905-017-0449-0.
10
Biological effects of combined resveratrol and vitamin D3 on ovarian tissue.白藜芦醇和维生素 D3 联合对卵巢组织的生物学效应。
J Ovarian Res. 2017 Sep 15;10(1):61. doi: 10.1186/s13048-017-0357-9.